About NATi, the Nucleic Acid Therapeutics Initiative hosted by A*STAR, is Singapore's national platform dedicated to advancing RNA-based medicines and revolutionising drug and vaccine development. NATi's mission is to establish Singapore as a globally recognised hub of excellence in nucleic acid therapeutics research, clinical translation and commercialisation. NATi focuses on key RNA modalities such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA) and messenger RNA (mRNA). To drive this vision, NATi is building a biotech‑like translational engine focused on asset and technology development spanning discovery to clinical development.

The Group Leader, Oligonucleotides Chemistry will oversee NATi's oligonucleotide chemistry capabilities spanning pre‑clinical synthesis, separation and analytical characterisation workflows. Beyond establishing robust SPOS‑based workflows, this role is instrumental in expanding...